Welcome to our dedicated page for Conmed news (Ticker: CNMD), a resource for investors and traders seeking the latest updates and insights on Conmed stock.
Conmed Corporation (CNMD) is a globally recognized medical technology company headquartered in Utica, New York. Specializing in the design, manufacturing, and distribution of surgical and patient monitoring products, Conmed plays a pivotal role in advancing healthcare outcomes. The company’s mission is to improve the quality of healthcare through innovative and high-quality medical solutions that empower healthcare professionals to deliver superior patient care.
Core Business Areas
Conmed operates across several key medical specialties, including:
- Orthopedics: Providing advanced surgical tools and implants for sports medicine and other orthopedic procedures.
- General Surgery: Offering devices and instruments designed to enhance surgical precision and efficiency.
- Gynecology: Delivering specialized products tailored for women’s health and minimally invasive procedures.
- Gastroenterology and Pulmonology: Supplying innovative solutions for diagnostic and therapeutic interventions in the digestive and respiratory systems.
- Anesthesiology: Developing patient monitoring systems that ensure safety and reliability during surgical procedures.
Global Reach and Market Presence
With a strong presence in the United States, Europe, the Middle East, Africa, Asia Pacific, and North America, Conmed serves a diverse range of healthcare providers worldwide. Its products are trusted by surgeons and medical professionals across multiple specialties, showcasing its commitment to enhancing patient outcomes on a global scale.
Business Model and Revenue Generation
Conmed generates revenue through the direct sale of its medical devices and equipment to hospitals, surgical centers, and healthcare institutions. By focusing on customer satisfaction and building long-term partnerships, the company ensures a steady demand for its innovative solutions. Its emphasis on research and development enables the continuous introduction of cutting-edge technologies that address evolving medical needs.
Competitive Landscape
Operating within the highly competitive medical technology industry, Conmed faces competition from major players such as Medtronic, Stryker, and Johnson & Johnson. The company differentiates itself through its customer-centric approach, commitment to quality, and targeted focus on specific medical specialties. Its ability to innovate and adapt to changing healthcare trends further strengthens its market position.
Commitment to Excellence
Conmed's dedication to improving healthcare extends beyond its products. The company prioritizes thoughtful leadership, employee development, and community engagement. By fostering a culture of innovation and responsibility, Conmed reinforces its role as a trusted partner in the global medical community.
Conclusion
Conmed Corporation exemplifies the integration of cutting-edge technology and a customer-first philosophy within the medical device industry. Its focus on enhancing clinical outcomes, coupled with a robust global presence, positions the company as a key contributor to the advancement of healthcare worldwide. By continuously innovating and maintaining high standards of quality, Conmed remains a vital player in the ever-evolving medical technology landscape.
CONMED (NYSE: CNMD) announced that Mark Kaye will join its Board of Directors effective February 24th, 2025. Kaye brings extensive experience in finance, accounting, risk management, strategic planning, and operational efficiencies, along with expertise in corporate governance and healthcare.
Kaye currently serves as Executive Vice President and Chief Financial Officer of Elevance Health since 2023. His previous roles include EVP and CFO at Moody's (2021-2023), SVP-CFO at Moody's (2018-2021), and leadership positions at MassMutual and Voya Financial. He has served as a Director on the Board of BCS Financial since 2024.
Both Martha Goldberg Aronson, Chair of CONMED's Board, and Patrick Beyer, President and CEO, expressed enthusiasm about Kaye's addition, highlighting how his healthcare and financial expertise will help guide CONMED's growth opportunities to benefit customers, shareholders, and employees.
CONMED (NYSE: CNMD) has announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share. The dividend was declared on February 24, 2025, and will be payable on April 4, 2025.
This payment will be distributed to all shareholders who are on record as of March 14, 2025. The announcement was made from CONMED's location in Largo, Florida.
CONMED (NYSE: CNMD) reported its Q4 and full-year 2024 financial results. In Q4, sales reached $345.9 million, up 5.8% year-over-year, with domestic revenue increasing 6.8% and international revenue growing 4.4%. Q4 GAAP earnings per share were $1.08, while adjusted EPS reached $1.34, up 26.4% from Q4 2023.
For full-year 2024, sales totaled $1,307.0 million, a 5.0% increase, with domestic revenue up 6.9% and international revenue rising 2.6%. Full-year GAAP EPS was $4.25, with adjusted EPS at $4.17, up 20.9% from 2023.
Looking ahead to 2025, CONMED projects revenue between $1.344-1.372 billion, representing 4-6% constant currency growth, and adjusted EPS of $4.25-$4.40, factoring in currency headwinds but excluding potential tariff impacts.
CONMED (NYSE: CNMD) has announced it will release its fourth quarter 2024 financial results after market close on Wednesday, February 5, 2025. The company will host a conference call at 4:30 p.m. ET on the same day to discuss the results. Interested parties can pre-register for the telephone conference, and a webcast will be available through the Investors section of CONMED's website. A replay of the webcast will be accessible approximately one hour after the call concludes.
CONMED (NYSE: CNMD) has announced its upcoming participation in the J.P. Morgan Healthcare Conference. The company's leadership, including President and CEO Patrick J. Beyer and Executive Vice President and CFO Todd W. Garner, will deliver a presentation on Monday, January 13, 2025, at 4:30 p.m. PT (7:30 p.m. ET) in San Francisco, CA.
Investors and interested parties can access a live audio webcast of the presentation through the "Investors" section on CONMED's website at www.conmed.com. The presentation will also be available for replay after the event.
CONMED (NYSE: CNMD) has announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share. The dividend will be paid on January 3, 2025, to shareholders of record as of December 20, 2024. The dividend declaration was made on December 9, 2024.
CONMED (NYSE: CNMD) announced its leadership team's upcoming participation in a fireside chat at the Piper Sandler Healthcare Conference. President and CEO Curt R. Hartman, EVP and CFO Todd W. Garner, and COO Pat J. Beyer will represent the company at the event scheduled for December 3, 2024, at 12:30 p.m. ET. The session will be accessible via live video webcast through CONMED's website investor section and will remain available for replay after the event.
CONMED (NYSE: CNMD) has announced its participation in two upcoming investor conferences in November 2024. The company will participate in fireside chats at the Stifel Healthcare Conference in New York on November 19 at 8:35 a.m. ET, featuring President and CEO Curt R. Hartman and VP of U.S. Orthopedics Nate Miersma. The second presentation will be at the Jefferies London Healthcare Conference on November 20 at 11:00 a.m. GMT, featuring EVP and CFO Todd W. Garner and COO Pat J. Beyer. Both sessions will be available via webcast through CONMED's website investor section.
CONMED (NYSE: CNMD) announced its third-quarter 2024 financial results. Sales reached $316.7 million, marking a 4.0% year-over-year increase as reported and 4.3% in constant currency. Diluted net earnings per share (GAAP) were $1.57, compared to $0.50 in the third quarter of 2023. Adjusted diluted net earnings per share rose by 16.7% to $1.05. The company announced that COO Patrick Beyer will succeed Curt Hartman as President and CEO effective January 1, 2025. The updated full-year revenue guidance is now $1.300 billion to $1.305 billion, slightly down from the prior range of $1.305 billion to $1.315 billion. Full-year adjusted diluted net earnings per share are expected to be in the range of $4.00 to $4.05, up from the prior range of $3.95 to $4.02. Foreign currency impact is expected to be immaterial on both revenue and earnings per share for the full year.
CONMED (NYSE: CNMD) announced a leadership transition as CEO Curt R. Hartman will retire effective January 1, 2025. Current COO Patrick Beyer will succeed as President and CEO. During Hartman's 10-year tenure, CONMED nearly doubled revenues and more than doubled profitability through portfolio expansion and strategic acquisitions. Martha Goldberg Aronson will become Board Chair on October 31, 2024. Hartman will continue as a Director through December 2024 and remain as an advisor until March 2027. Beyer, who joined CONMED in 2014, has served in various leadership roles including President of International and Global Orthopedics, leading key acquisitions like In2Bones and BioRez.
FAQ
What is the current stock price of Conmed (CNMD)?
What is the market cap of Conmed (CNMD)?
What does Conmed Corporation specialize in?
What are the key medical specialties Conmed serves?
How does Conmed generate revenue?
What is Conmed's competitive advantage?
Where is Conmed Corporation headquartered?
What is Conmed's global presence?
What is Conmed's mission?
Who are Conmed's main competitors?
What industries does Conmed operate in?
How does Conmed contribute to healthcare innovation?
